Advertisement

International Journal of Hematology

, Volume 83, Issue 2, pp 156–158 | Cite as

Successful Reduced-Intensity Hematopoietic Stem Cell Transplantation in Myelodysplastic Syndrome with Severe Coronary Artery Disease

  • Shigeki Kosugi
  • Makoto Hirokawa
  • Yoshinari Kawabata
  • Hitoshi Hasegawa
  • Tomoko Yoshioka
  • Ikuo Miura
  • Ken-ichi Sawada
Case Report
  • 48 Downloads

Abstract

A 60-year-old Japanese man with myelodysplastic syndrome (MDS) and effort angina was referred to our clinic for treatment of MDS.The patient was transfusion-dependent and displayed coronary artery disease (CAD) with 99% obstruction of the left anterior descending coronary artery. Treatment comprised reduced-intensity hematopoietic stem cell transplantation with administration of fludarabine phosphate (180 mg/m2) and busulfan (8 mg/kg), followed by allogeneic peripheral blood stem cell transplantation from an HLA-matched sister. The regimen was well tolerated, and engraftment occurred rapidly without any therapy-related complications, including cardiovascular attack. Sex chromosome analysis by fluorescence in situ hybridization revealed complete donor chimerism on day 29 for bone marrow cells and on day 59 for peripheral blood leukocytes. The patient became transfusion-independent on posttransplantation day 8. As of 22 months postoperatively, he remains well, with 100% Karnofsky performance status, a limited type of chronic graft-versus-host disease, and no recurrence of disease. The clinical course of the patient suggests that this preparative regimen allows safe allogeneic stem cell transplantation for MDS patients with severe CAD.

Key words

Reduced-intensity hematopoietic stem cell transplantation Myelodysplastic syndrome Coronary artery disease 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Greenberg PL. The myelodysplastic syndromes. In: Hoffman R, Benz E, Shattil S, et al, eds. Hematology: Basic Principals and Practice. 3rd ed. New York, NY: Churchill Livingstone; 2000:1106–1129.Google Scholar
  2. 2.
    Bowen D, Culligan D, Jowitt S, et al, for the UK MDS Guidelines Group. Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br J Haematol. 2003;120:187–200.CrossRefGoogle Scholar
  3. 3.
    Luger S, Sacks N. Bone marrow transplantation for myelodysplastic syndrome-who? when? and which? Bone Marrow Transplant. 2002;30:199–206.CrossRefGoogle Scholar
  4. 4.
    Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood. 1997;89:4531–4536.PubMedGoogle Scholar
  5. 5.
    Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998;91:756–763.PubMedGoogle Scholar
  6. 6.
    Khouri IF, Keating M, Korbling M, et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol. 1998;16:2817–2824.CrossRefGoogle Scholar
  7. 7.
    Childs R, Chernoff A, Contentin N, et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med. 2000;343:750–758.CrossRefGoogle Scholar
  8. 8.
    Bennett JM, Catovsky MT, Daniel G, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51:189–199.CrossRefGoogle Scholar
  9. 9.
    Greenberg P, Cox C, Le Beau M, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079–2083.PubMedGoogle Scholar
  10. 10.
    Eagle KA, Berger PB, Calkins H, et al. ACC/AHA guideline update for perioperative cardiovascular evaluation for noncardiac surgery update: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee to Update the 1996 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). 2002. American College of Cardiology Web site. Available at: http://www.acc.org/ clinical/guidelines/perio/update/perupdate_index.htm.Google Scholar
  11. 11.
    Sakaida E, Nakaseko C, Harima A, et al. Late-onset noninfectious pulmonary complications after allogeneic stem cell transplantation are significantly associated with chronic graft-versus-host disease and with the graft-versus-leukemia effect. Blood. 2003;102:4236–4242.CrossRefGoogle Scholar
  12. 12.
    Hertenstein B, Stefanic M, Schmeiser T, et al. Cardiac toxicity of bone marrow transplantation: predictive value of cardiologic evaluation before transplant. J Clin Oncol. 1994;12:998–1004.CrossRefGoogle Scholar
  13. 13.
    Goldberg SL, Klumpp TR, Magdalinski AJ, Mangan KF. Value of the pretransplant evaluation in predicting toxic day-100 mortality among blood stem-cell and bone marrow transplant recipients. J Clin Oncol. 1998;16:3796–3802.CrossRefGoogle Scholar
  14. 14.
    Ghobrial IM, Bunch TJ, Caplice NM, Edwards WD, Miller DV, Litzow MR. Fatal coronary artery disease after unrelated donor bone marrow transplantation. Mayo Clin Proc. 2004;79:403–406.CrossRefGoogle Scholar
  15. 15.
    Saccardi R,Tyndall A, Coghlan G, et al. Consensus statement concerning cardiotoxicity occurring during haematopoietic stem cell transplantation in the treatment of autoimmune diseases, with special reference to systemic sclerosis and multiple sclerosis. Bone Marrow Transplant. 2004;34:877–881.CrossRefGoogle Scholar
  16. 16.
    Hensley ML, Schuchter LM, Lindley C, et al. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol. 1999;17:3333–3355.CrossRefGoogle Scholar
  17. 17.
    Arruda JA, Costa MA, Brito FS Jr, et al. Effect of systemic immunosuppression on coronary in-stent intimal hyperplasia in renal transplant patients. Am J Cardiol. 2003;91:1363–1365.CrossRefGoogle Scholar
  18. 18.
    Stamm C,Westphal B, Kleine HD, et al. Autologous bone-marrow stem-cell transplantation for myocardial regeneration. Lancet. 2003;361:45–46.CrossRefGoogle Scholar
  19. 19.
    Wang FS, Trester C. Bone marrow cells and myocardial regeneration. Int J Hematol. 2004;79:322–327.CrossRefGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2006

Authors and Affiliations

  • Shigeki Kosugi
    • 1
  • Makoto Hirokawa
    • 1
  • Yoshinari Kawabata
    • 1
  • Hitoshi Hasegawa
    • 2
  • Tomoko Yoshioka
    • 1
  • Ikuo Miura
    • 1
  • Ken-ichi Sawada
    • 1
  1. 1.Divisions of aHematology and Oncology, Department of MedicineAkita University School of MedicineAkitaJapan
  2. 2.Cardiovascular Medicine, Department of MedicineAkita University School of MedicineAkitaJapan

Personalised recommendations